Cash/Burn From SEC Filing For Period: 

Q1 '20

GNFT

GENFIT

GENFIT is a late-stage biopharmaceutical company dedicated to the discovery and development of innovative therapeutic and diagnostic solutions in metabolic and liver related diseases where there are considerable unmet medical needs, corresponding to a lack of approved treatments.

Cash

$310.4M

Burn Rate

-$7.9M

Amp Analysis

Pipeline Information

Click drug data to see upcoming trial info and prior data

Drug | Disease

Stage | Exp Date

Prior Data

Elafibranor

Non-alcoholic steatohepatitis (NASH)

Phase 3 Full Data Set Review

Second half of 2020

Elafibranor

Primary Biliary Cholangitis

Phase 3

TBD

Nitazoxanide

NASH-induced significant or severe fibrosis

Phase 2

TBD

TGFTX1

Psoriasis or Respiratory Conditions

Pre-Clinical

TBD

Recent Posts

See What The Community Is Saying - Click To See Full Post

*Disclaimer: Information provided on ampbiotechresearch.com and in any of our reports, products and services are for information only and are not investment advice. Please consult with an investment adviser and do your own diligence before making any investment decisions or taking any action.  By accessing this site, you agree to our Terms of Use and Privacy Policy that can be accessed here. Amp Core™ is a trademark of Amp Biotech Research, LLC

©2020 BY Amp Biotech Research

PROUDLY CREATED WITH WIX.COM

  • Twitter Social Icon
  • LinkedIn Social Icon